Who
Alan G. Levin
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals; Director, CervoMed; Director, Aceto; EVP, Chief Financial Officer, Endo Health Solutions; Senior Vice President, Pfizer.
In numbers
- Trades disclosed
- 132
- Buys
- 3
- Sells
- 4
- Bought
- $163K
- Sold
- $5.7M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 30 Dec 2005
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,181 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,933 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,820 at $0.00 | filing |
| 30 May 2024filed 31 May 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $50K7,861 at $6.36 | filing |
| 13 Jun 2023filed 15 Jun 2023 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,072 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,745 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,360 at $8.27 | filing |
| 28 Feb 2023filed 2 Mar 2023 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,271 at $8.85 | filing |
| 30 Nov 2022filed 2 Dec 2022 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K842 at $13.36 | filing |
| 31 Aug 2022filed 2 Sep 2022 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K809 at $13.90 | filing |
| 7 Jun 2022filed 9 Jun 2022 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,022 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,866 at $0.00 | filing |
| 31 May 2022filed 2 Jun 2022 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,138 at $9.31 | filing |
| 28 Feb 2022filed 2 Mar 2022 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $9,999602 at $16.61 | filing |
| 30 Nov 2021filed 2 Dec 2021 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $9,998829 at $12.06 | filing |
News
Pfizer layoffs announced at Rocky Mount, Sanford facilities in NCPFE · abc11.com · 21 Oct 2026Critical Analysis: Nexentis Technologies (NASDAQ:NXTS) versus Pfizer (NYSE:PFE)PFE · dailypolitical.com · 19 Oct 2026Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?PFE · fool.com · 19 Oct 2026
0 headlines in the last 90 days name Alan G. Levin; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.